ADA and infection: Patients previously enrolled in the US Phase 3 study (STP group) and 66.7% of those transitioning from pegademase (PT group) also maintained satisfactory ADA and dAXP levels with stable rates of infections, hospitalizations, and lymphocyte counts for up to 48.6 months.